Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news


From To
Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%

RBC Capital Markets analyst Brian Abrahams specifically mentioned a somewhat surprising reason to be excited about Gilead's prospects. He thinks that experimental HIV drug GS-6207 could be a transformative catalyst for Gilead. But GS-6207 is only in phase 1 clinical testing. It could take years for the drug to reach the market.

24 March 2019
Motley Fool
Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo (ibalizumab-uiyk) plus an optimized background regimen.

20 March 2019
Italy's therapeutic AIDS vaccine shows drastic reduction of HIV virus reservoirs: study

Clinical trials of an Italian therapeutic vaccine against AIDS showed a drastic reduction of virus reservoirs in treated patients, Italian researchers said on Wednesday.

14 March 2019
CROI 2019: Will the “Düsseldorf patient” make three — further propelling cure research?

Five years after a stem cell transplant with the same critical factor as those received by the Berlin patient and the London patient, and four months after stopping antiretroviral treatment, a Düsseldorf man remains virally suppressed

12 March 2019
Science Speaks
Wider ART Rollout Tied to Declines in HIV Mortality in Kenya

Both all-cause mortality and mortality among HIV-positive people dropped in Western Kenya following a scale-up of antiretroviral therapy (ART), a researcher said here. From 2011 to 2016, all-cause mortality dropped from 10.0 per 1,000 person years (95% CI 8.4-11.7) to 7.5 per 1,000 person years (95% CI 5.8-9.1), reported Emily C. Zielinski-Gutierrez, DrPH, of the CDC.

12 March 2019
MedPage Today
HIV Drug Aiming to Free Patients From Daily Doses Nears Market

A once-a-month shot promising to free patients from daily doses of treatment for HIV, the virus that causes AIDS, is expected to reach the market early next year after hitting goals in a pair of studies.

08 March 2019
Has a second person with HIV been cured?

“This is a big deal,” says Sharon Lewin, who heads the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia. “It tells us that Timothy Brown wasn’t a one-off.” Although the interventions that the two patients received could only be used on a tiny fraction of the 37 million HIV-infected people worldwide, their stories point to cure strategies that could be more widely applicable.

06 March 2019
Science Magazine
Planner sentenced for role in £60m 'HIV cure' investment scam

Two fraudsters who attempted to steal more than £60m through a fraudulent tax avoidance investment scheme claiming to invest in HIV research have been jailed for a total of 14 and a half years.

26 February 2019
Financial Planning Today
Using anti-cancer immunotherapy to fight HIV

Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple therapy. In a study published in the journal Nature Communications, they show, in the cells of people living with HIV, how these therapies reveal the virus - until now hidden in the hollows of infected cells - to the immune system.

20 February 2019
Eurekalert Medicine & Health
Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

Several randomized controlled trials have shown dolutegravir monotherapy to be inferior to cART. These dolutegravir monotherapy trials, however, have been conducted in patients initiating cART during chronic rather than primary HIV infection. Since patients who start cART during the early phase of HIV infection show a reduced HIV reservoir and low viral diversity, the researchers evaluated whether these properties would allow for sustained virologic suppression after a switch to dolutegravir monotherapy.

15 February 2019
Infectious Disease Advisor
← First12345...97Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.